Predict your next investment

Asset/Investment Management
tybournecapital.com

See what CB Insights has to offer

Investments

23

Portfolio Exits

4

Funds

3

About Tybourne Capital Management

Tybourne Capital Management operates as an investment advisory firm in Hong Kong.

Tybourne Capital Management Headquarter Location

2302 Cheung Kong Center 2 Queen's Road Central

Hong Kong

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Tybourne Capital Management News

Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Mu...

Jan 7, 2022

Proceeds to advance clinical development of WU-NK-101 for relapsed/refractory AML, and initiate studies in solid tumor indications. Oversubscribed Series B co-led by Abingworth and Tybourne Capital Management, and joined by Fidelity Management & Research Company and Intermediate Capital Group (ICG) as well as existing investors RiverVest Venture Partners, LYZZ Capital, and Lightchain Capital. Wugen technology licensed from Washington University in St. Louis. ST. LOUIS, MO and SAN DIEGO, CA, July 15, 2021 – Wugen, Inc. , a clinical stage biotechnology company developing a pipeline of off-the-shelf cell therapies, today announced the completion of an oversubscribed $172 million Series B financing led by Abingworth and Tybourne Capital Management, and joined by new investors Fidelity Management & Research Company, Intermediate Capital Group (ICG), Sands Capital, Aisling Capital Management, Alexandria Venture Investments, Velosity Capital and Falcon Edge Capital. Existing investors, including RiverVest Venture Partners, LYZZ Capital, and Lightchain Capital, also participated. In connection with the financing, Bali Muralidhar, M.D., Ph.D., Managing Partner at Abingworth, Bosun Hau, Managing Director at Tybourne Capital Management, and Peter Kiener, Ph.D., Venture Partner at ICG, will join Wugen’s Board of Directors. The proceeds of the financing will support further clinical development of Wugen’s best-in-class memory natural killer (NK) cell platform and advance ongoing trials for patients with severe acute myelogenous leukemia (AML) and other oncology indications, including solid tumors. Wugen also plans to apply these proceeds to advance its broader pipeline of next-generation products into the clinic, including its allogeneic CD7-targeted CAR-T cell therapy to treat T-cell leukemia and lymphoma. Dan Kemp, Ph.D., President and Chief Executive Officer of Wugen, said, “We have tremendous confidence that our off-the-shelf memory NK cell platform will give rise to a significant pipeline of highly effective and safe anti-cancer therapies. In an ongoing Phase 1/2 clinical trial, our lead product WU-NK-101 has demonstrated an impressive complete response rate in relapsed/refractory AML and we look forward to advancing into a global multi-center study later this year. In parallel, we’re also pursuing solid tumor indications both as monotherapy and in combination with antibody drugs. The rapid growth of the company could not have happened without the commitment of RiverVest Venture Partners, and in particular the vision and leadership of John McKearn as our founding CEO.” “We’re delighted to welcome these premier investors as Wugen stakeholders as we build on the significant potential for the company’s unique memory NK cell platform,” said John McKearn, Ph.D., Managing Director at RiverVest Venture Partners and Chairman of the Board of Directors of Wugen. “This significant capital raise will enable Wugen to advance its off-the-shelf cell therapies to develop a broad and differentiated oncology pipeline.” Wugen’s memory NK cell platform, with enhanced tumor-killing functionality and in vivo persistence, is designed to overcome the limitations of conventional NK cell therapies. In clinical studies, WU-NK-101 was shown to be highly effective against AML, including in patients with a high burden of disease, and without causing cytokine release syndrome (CRS) or neurotoxicity. Wugen utilizes its proprietary GMP-grade fusion molecules to manufacture and scale its memory NK cell products using cells from healthy donors. In addition, Wugen’s feeder cell-free expansion and cryopreservation method enables an off-the-shelf treatment approach, with the opportunity for streamlined global distribution and convenient outpatient dosing for cancer patients. “We’re excited to participate in this financing round with Wugen and are confident this exceptional team will deliver on the promise of memory NK cells,” added Bali Muralidhar, M.D., Ph.D., Managing Director at Abingworth. “We believe that Wugen’s strong collaborative partnership with Washington University is also a key strength, especially at the translational level, where co-founders and world-class investigators Todd Fehniger, M.D., Ph.D., John DiPersio, M.D., Ph.D., Melissa Berrien-Elliott, Ph.D., and Matt Cooper, Ph.D., who is also Wugen’s Chief Scientific Officer, provide critical support.” About Wugen Wugen, Inc., is a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory natural killer (NK) cell therapies to treat a broad range of hematological and solid tumor malignancies. Memory NK cells are hyper-functional, long-lasting immune cells that have evolved to attack cancer and respond to infection. Wugen is harnessing the power of this rare cell population by using its proprietary technologies to create WU-NK-101, currently in clinical development for acute myelogenous leukemia (AML). In addition, Wugen is developing a pipeline of programs targeting solid tumor indications. For more information, please visit  www.wugen.com . About Abingworth Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies. Since 1973, Abingworth has invested in over 170 life science companies, leading to 44 M&As and 71 IPOs. Abingworth’s therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston. For more information, please visit  www.abingworth.com . About Tybourne Tybourne Capital Management is a global growth investor in public and private equity markets, focusing on investments in the Healthcare, Consumer, Financials and TMT sectors. The firm was founded in 2012 and is headquartered in Hong Kong with an office in San Francisco. Tybourne manages long duration capital on behalf of prominent non-profits, university endowments, sovereigns, corporate pensions and family offices. For more information, please visit www.tybournecapital.com . Wugen

Tybourne Capital Management Investments

23 Investments

Tybourne Capital Management has made 23 investments. Their latest investment was in UPSIDER as part of their Series C on May 5, 2022.

CBI Logo

Tybourne Capital Management Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/11/2022

Series C

UPSIDER

$37.63M

Yes

2

3/23/2022

Series A

jinjer

$42.18M

Yes

NTT DoCoMo Ventures, SBI Group, Undisclosed Investors, and Undisclosed Venture Investors

3

3/14/2022

Secondary Market

with

Yes

1

12/27/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

11/25/2021

Series D

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/11/2022

3/23/2022

3/14/2022

12/27/2021

11/25/2021

Round

Series C

Series A

Secondary Market

Series C

Series D

Company

UPSIDER

jinjer

with

Subscribe to see more

Subscribe to see more

Amount

$37.63M

$42.18M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

NTT DoCoMo Ventures, SBI Group, Undisclosed Investors, and Undisclosed Venture Investors

Sources

2

3

1

10

10

Tybourne Capital Management Portfolio Exits

4 Portfolio Exits

Tybourne Capital Management has 4 portfolio exits. Their latest portfolio exit was Amylyx Pharmaceuticals on January 07, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/7/2022

IPO

6

11/1/2021

IPO

Subscribe to see more

Subscribe to see more

10

9/7/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

3/12/2015

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/7/2022

11/1/2021

9/7/2021

3/12/2015

Exit

IPO

IPO

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

6

10

10

10

Tybourne Capital Management Fund History

3 Fund Histories

Tybourne Capital Management has 3 funds, including Tybourne Strategic Opportunities (Feeder) Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

7/23/2019

Tybourne Strategic Opportunities (Feeder) Fund

$77.5M

1

Tybourne Capital Management Fund I

$99M

10

Tybourne Strategic Opportunities Fund

10

Closing Date

7/23/2019

Fund

Tybourne Strategic Opportunities (Feeder) Fund

Tybourne Capital Management Fund I

Tybourne Strategic Opportunities Fund

Fund Type

Status

Amount

$77.5M

$99M

Sources

1

10

10

Tybourne Capital Management Team

1 Team Member

Tybourne Capital Management has 1 team member, including current Managing Director, Bosun Hau.

Name

Work History

Title

Status

Bosun Hau

Managing Director

Current

Name

Bosun Hau

Work History

Title

Managing Director

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.